Terragen Holdings unveils capital raising strategy

Terragen Holdings (ASX:TGH) has announced an equity raising initiative to gather A$5.0 million. The funds will support scientific research and development and global commercialization efforts. The equity raising includes a non-underwritten institutional placement and a fully underwritten pro-rata entitlement offer.

Overview of Terragen Holdings' equity raising and future plans

Terragen Holdings (ASX:TGH) is set to raise A$5.0 million through a combination of an institutional placement and an entitlement offer. This initiative aims to bolster the company's research and development capabilities and accelerate its global market entry. The capital will support the development of Terragen's MYLO and GLP products, along with general working expenses. The company is making strategic moves like forging distribution agreements and planning product launches to enhance its market presence. With a strengthened cash position, Terragen is well-positioned to pursue its growth ambitions in the agricultural biotechnology sector.

Insights from Terragen Holdings leadership

Our focus is on commercializing freeze-dried probiotics and expanding our market presence,' emphasized CEO Richard Norton.